Welcome to our dedicated page for KIORA PHARMACEUTICALS news (Ticker: KPRX), a resource for investors and traders seeking the latest updates and insights on KIORA PHARMACEUTICALS stock.
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule therapies for retinal diseases. Company news centers on its ophthalmology pipeline, including KIO-301, a molecular photoswitch program for retinitis pigmentosa, choroideremia and Stargardt disease, and KIO-104, a non-steroidal DHODH inhibitor for retinal inflammation.
Recurring updates include clinical-study publications and development progress, intellectual-property coverage for KIO-100 family formulations, collaboration and regional partnership activity, research-and-development spending, capital resources, equity financing, warrant transactions and management changes. Financial releases generally pair operating results with status reports on the company’s retinal-disease programs.
Kiora Pharmaceuticals (NASDAQ: KPRX) reported Q1 2026 results and a clinical update. Key points: ABACUS-2 enrollment is active and nearly 50% complete; ABACUS-1 data published in Nature Medicine; KLARITY (KIO-104) is approaching a planned safety review; quarter-end cash and short-term investments were $13.9 million, with $5.0 million raised subsequent to quarter end. The company notes collaboration receivables of $1.5 million from Théa and believes it has an operational runway into late 2028.
Kiora Pharmaceuticals (NASDAQ: KPRX) reported publication of Phase 1 ABACUS-1 results for KIO-301 in Nature Medicine on April 14, 2026. The open-label, dose-escalation study dosed 12 eyes in six participants and met the primary 30-day ocular and systemic safety endpoint with no serious adverse events.
Exploratory findings included temporal changes in functional vision, light-induced fMRI activity in visual cortex, and improved participant-reported quality-of-life; a randomized, controlled Phase 2 trial (ABACUS-2) has been initiated to evaluate higher doses and functional endpoints.
Kiora Pharmaceuticals (NASDAQ: KPRX) closed a private placement providing up to $24 million in gross proceeds, including $5.0 million upfront and up to $19 million via milestone-based warrants. The transaction closed April 6, 2026 and was priced at-the-market under Nasdaq rules.
Each share (or pre-funded warrant) sold with four short-term Tranche A-1 warrants and one Tranche A-2 warrant at a combined purchase price of $2.543. All common warrants are immediately exercisable at $1.94, and the company will file a resale registration statement covering the issued securities.
Kiora Pharmaceuticals (NASDAQ: KPRX) announced that Eric J. Daniels, M.D., MBA will depart as Chief Development Officer effective April 17, 2026, and the company has begun a search for his successor.
Kiora said it remains focused on advancing its retinal disease pipeline; enrollment continues for KIO-301 and KIO-104. According to the company, ABACUS-2 (KIO-301) cleared enrollment for the remaining 50µg cohort and initiation of the 100µg cohort, while KLARITY (KIO-104) cleared all planned safety checkpoints and continues enrolling patients.
Kiora Pharmaceuticals (NASDAQ: KPRX) reported Q4 and full-year 2025 results and advanced two Phase 2 retinal trials: ABACUS-2 (KIO-301) and KLARITY (KIO-104).
Key facts: $17.1M cash plus $3.5M receivables, 2025 net loss $10.8M, cash runway into late 2027, Senju option agreement up to $110M, and anticipated initial clinical readouts in 2027.
Kiora Pharmaceuticals (NASDAQ: KPRX) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 3:20 p.m. ET.
A live webcast will be available on the company's investor relations website ir.kiorapharma.com, with a replay accessible for approximately 90 days.
Kiora Pharmaceuticals (NASDAQ: KPRX) appointed retina specialist Dr. Taiji Sakamoto to its Scientific Advisory Board on January 27, 2026. Dr. Sakamoto, chair of ophthalmology at Kagoshima University, will advise on clinical and scientific strategy for retinal therapeutics including non-steroidal approaches such as KIO-104. He has led research in diabetic retinopathy, retinal surgery, ocular angiogenesis, published over 460 peer-reviewed papers and held leadership roles in JRVS and international ophthalmology organizations.
Kiora Pharmaceuticals (NASDAQ: KPRX) announced that the U.S. Patent and Trademark Office issued U.S. patent US-12,472,263 on December 1, 2025 covering additional, novel formulations of the KIO-100 family, including a specific formulation of the API in KIO-104.
The API in KIO-104 is a non-steroidal DHODH inhibitor formulated for local retinal delivery. The company is actively screening and dosing in the multicenter Phase 2 KLARITY trial, enrolling up to 28 patients across retinal inflammatory conditions including posterior non-infectious uveitis and diabetic macular edema. KIO-104 previously demonstrated clinical proof-of-concept in a Phase 1 trial in non-infectious uveitis.
Kiora Pharmaceuticals (NASDAQ: KPRX) reported third quarter 2025 results and clinical updates on two Phase 2 retinal trials. The company ended the quarter with $19.4 million in cash, cash equivalents and short-term investments, plus $1.2 million collaboration receivables and $1.5 million tax and research credit receivables.
Kiora said it continues to recruit and dose patients in KLARITY (KIO-104, retinal inflammation) and ABACUS-2 (KIO-301, retinitis pigmentosa). R&D expense was $2.7 million in Q3 2025 (partially offset by $1.7 million reimbursable expenses from Théa) versus $2.1 million in Q3 2024. The company reported net income $27 thousand for Q3 2025 versus a net loss of $3.4 million in Q3 2024 and expects cash runway into late 2027.
Kiora Pharmaceuticals (NASDAQ: KPRX) announced on October 30, 2025 that it joined Global Genes' RARE-X Vision Consortium, a corporate‑nonprofit collaboration to accelerate research and development of therapies for rare ocular disorders.
The consortium will build a de‑identified, individual‑level global data repository to support patient identification and recruitment, define meaningful outcome measures by aggregating functional, structural, and patient‑reported data, and promote inclusive study design with patient input. Kiora's CEO, Brian Strem, said the collaboration aims to increase the probability of advancing Kiora's experimental inherited retinal disease therapy toward patients.